Denovo Biopharma LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Denovo Biopharma LLC
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.
Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Other Names / Subsidiaries
- Denovo Biomarkers